Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (585)	4/8/1999 10:49:00 PM
From: LLCF	Read Replies (2) of 4974

< NBI-34060 is Sonata (zaleplon) sister (or back-up) compound, So does this mean that AHP won't push to get the compound going??? Seems unfair. I noticed that the press release stated "with improved side-effect profile relative to currently available drugs" does that include Sonata... or do they mean GABA(A) in general... also, if these drugs are very similar shouldn't it "fly to approval quickly"???? DAK PS... are you saying this compound is still "unpartnered"?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next